Chiang RS et al., 2021-02-10: Stanford/University of Washington case series of three genitourinary cancer patients who took fenbendazole 1 g three times weekly alongside standard therapy and showed complete or near-complete radiographic responses; the authors themselves concede the first patient may have responded to nivolumab alone.
It is possible that our first patient with mRCC would have achieved a significant response to nivolumab alone without FBZ.
3
Chiang RS et al., 2021-02-10: Stanford/University of Washington case series of three genitourinary cancer patients who took fenbendazole 1 g three times weekly alongside standard therapy and showed complete or near-complete radiographic responses; the authors themselves concede the first patient may have responded to nivolumab alone. Study type: retrospective case series, n=3, USA. Patients: (1) 63M metastatic clear-cell renal cell carcinoma, FBZ 1 g three times per week started during/after three doses of nivolumab 240 mg, near-complete resolution on MRI, 10 months without recurrence; (2) 72M metastatic urothelial carcinoma of urethra, FBZ 1 g orally three days per week plus vitamin E 800 mg/day, curcumin 600 mg/day and CBD oil, aortocaval node shrank from 2.0×1.5 cm to 0.5×0.5 cm over 9 months; (3) 63F bladder urothelial carcinoma, FBZ 1 g three times weekly concurrent with TURBT and AMVAC chemotherapy, 7.5 cm mass resolved. Dose/route/schedule as published: 1 g orally three times weekly (not weight-based); form not specified; no duration limit stated. Funding: none declared; the paper carries no funding or conflict-of-interest statement (the PDF has no disclosure section). Comparator: none. Measured by serial MRI/CT/PET. Journal is SciTechnol, a pay-to-publish publisher, and the article is not indexed in PubMed. Quote verified against the PDF's default-mode text extraction because the two-column layout interleaves under -layout. Study type: uncontrolled series.
